Compare Abbott Laboratories (ABT) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Victoria's Secret & Co — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Victoria's Secret & Co trades at $76.06 (market cap $6.22B). The key difference: Abbott Laboratories is far larger — about 26.8× Victoria's Secret & Co's market cap, and Abbott Laboratories pays a 2.63% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| ABT | VSXY | |
|---|---|---|
Market Cap | $166.94B | $6.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $88.50 |
52-Week Low | $82.57 | $17.70 |
Enterprise Value | $193.69B | $8.86B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Victoria's Secret (VSXY) trades at $78.25, up 2.01% with strong momentum as the stock benefits from international expansion and improved fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.60 surpassing the $0.32 estimate. Technical indicators show a neutral overall signal while the stock trades near pivot point resistance at $78. Analyst consensus remains bullish with a $88.56 price target representing 13% upside potential.
The outlook appears positive with international sales growing 44.9% in Q1 2026 and margin recovery underway, though risks include competitive pressures and execution challenges in global expansion. With improving cash flow projections and shareholder support for management's strategy, VSXY offers growth potential but requires monitoring of consumer spending trends and inventory management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
